Login
Cardiovascular Systems NASDAQ: CSII
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases
| Name | Cardiovascular Systems |
| Ticker | CSII |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Medical Devices |
|
Price
52W Low/High |
41.30
27.86 / 47.19 |
| Momentum | Weak Down |
| Market cap | 1.7 B |
| 1Y Total Return |
9.78%
Below Average |
| 1Y Volatility |
52.08%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases
Details
| Ticker | CSII |
| Name | Cardiovascular Systems |
| ISIN | US1416191062 |
| CUSIP | 141619106 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Medical Devices |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 2/26/21
| Close Price | 41.30 |
| 52W Low/High | 27.86 / 47.19 |
| Market cap | 1.7 B |
| 1Y Total Return |
9.78%
Below Average |
| 1Y Volatility |
52.08%
Less Risk |
| Beta | 2.93 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -8.8% |
| Cash from Op. / Cur. Liabilities | -0.24 |
| Diluted Earnings / Share | -0.57 |
| ROE | - |
| ROIC | -11.3% |
| Price / Revenue | 7.0 |
| Price / Book | 5.9 |
| Price / CF | -140.0 |
| Current Ratio | 6.1 |
| Cur.Liabilities / Tot.Liabilities | 0.6 |
| Financial Leverage | 0.08 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
228
|
264
|
231
|
207
|
193
|
181
|
|
| Gross Profit |
180
|
212
|
188
|
168
|
156
|
143
|
|
| R&D |
40
|
40
|
28
|
24
|
23
|
30
|
|
| EBITDA |
-14
|
-1
|
7
|
2
|
-24
|
-44
|
|
| Operating Income |
-19
|
-8
|
2
|
-3
|
-28
|
-48
|
|
| Net Income exc. Extra |
-
|
-
|
2
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
39
|
34
|
34
|
33
|
33
|
33
|
|
| EPS exc. Extra |
-0.57
|
-0.21
|
0.04
|
-0.10
|
-0.87
|
-1.49
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
349
|
224
|
207
|
190
|
159
|
151
|
|
| Cash, Eq & Invt ShortTerm |
225
|
109
|
119
|
108
|
80
|
67
|
|
| Total Current Assets |
293
|
170
|
171
|
156
|
123
|
113
|
|
| Total Non-Current Assets |
56
|
55
|
36
|
34
|
36
|
38
|
|
| Intangibles |
16
|
21
|
5
|
5
|
5
|
5
|
|
| Total Liabilities |
75
|
81
|
69
|
66
|
47
|
30
|
|
| Total Current Liabilities |
48
|
53
|
39
|
33
|
32
|
28
|
|
| Long Term Debt |
27
|
28
|
30
|
33
|
14
|
2
|
|
| Shareholder equity |
274
|
143
|
139
|
124
|
112
|
121
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-11
|
5
|
14
|
5
|
8
|
-29
|
|
| Depreciation |
4
|
4
|
4
|
4
|
4
|
3
|
|
| Cash from Investing |
-115
|
-56
|
-5
|
-3
|
-1
|
-13
|
|
| Capex |
4
|
3
|
2
|
2
|
2
|
12
|
|
| Cash from Financing |
135
|
-2
|
2
|
26
|
7
|
6
|
|
| Stock Issued |
139
|
4
|
4
|
5
|
7
|
6
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
21
|
0
|
0
|
|
| Free Cash Flow |
-25
|
-3
|
2
|
-5
|
-22
|
-67
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
0.7%
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
836.3%
|
-
|
-
|
-
|
|
| Current Ratio |
6.1
|
3.2
|
4.4
|
4.7
|
3.8
|
4.0
|
|
| Financial Leverage D/E |
0.08
|
0.15
|
0.15
|
0.17
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-11.3%
|
-5.8%
|
7.5%
|
-4.1%
|
-54.0%
|
-89.7%
|
|
| Return on Shareholder Equity |
-
|
-
|
1.3%
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available